Journal: Frontiers in immunology

Article Title: Oocytes could rearrange immunoglobulin production to survive over adverse environmental stimuli.

doi: 10.3389/fimmu.2022.990077

Figure Lengend Snippet: FIGURE 4 IgG transcription increased and was regulated by H3K27ac (A) Amplification of IgG-VDJ region, cloning and sequencing shows that IgG-VDJ mRNA is present in the oocyte. (B) Parallel comparison of IgG-VDJ mRNA sequences from (A) shows that IgG-VDJ mRNAs are highly distinct between different oocytes. (C, D) Amplification of IgG constant (IgG-C) region showed that IgG-C mRNA levels significantly increased on exposure to either LPS or CSF1 stimuli. (E, F) H3K27ac chip-seq showed that on exposure to either LPS or CSF1 stimuli, H3K27ac decreased its binding to the regulating sequences of all genes however, its binding to the regulating sequences of the IgG gene significantly increased. (G) Magnified H3K27ac-binding regions in IgG regulating sequences showed that upon both CSF1 and LPS, H3K27ac increased its binding. Gapdh was used as a loading control. Difference lower-case letters indicate significant difference between two groups.

Article Snippet: LPS (Cat#: L2880, Sigma, St. Louis, MO, USA) was added into oocyte IVMmedium at a final conc. of 10 EU/ml for 16 hour; CSF1 (Cat#: HZ-1207, Proteintech, Rosemont, IL, USA) was added into oocyte IVMmedium at a final conc. of 10 ng/ml for 16 hour; H2O2 (Cat#:88597,Sigma,St.Louis,MO,USA)wasadded intooocyte IVM medium at a final conc. of 30 mM for 30 min; NMN (Cat#: S5259, Selleck Chemicals, Houston, TX, USA) was added into oocyte IVM medium at a final conc. of 1mM for 16 hour; SC75741 (Cat#: S7273, Selleck Chemicals, Houston, TX, USA) was added into oocyte IVM medium at a final conc. of 0.1 mM for 16 hour.

Techniques: Cloning, Sequencing, Comparison, ChIP-sequencing, Binding Assay, Control

Journal: Frontiers in immunology

Article Title: Oocytes could rearrange immunoglobulin production to survive over adverse environmental stimuli.

doi: 10.3389/fimmu.2022.990077

Figure Lengend Snippet: FIGURE 5 IgG functions to eliminate ROS production in response to CSF1 stimuli (A, B) Western blot and quantification show that on exposure to CSF1 stimuli, IgG levels significantly decreased about one-fold. NMN supplement significantly raised the IgG level close to the control level. (C, D) ROS live fluorescence shows that on exposure to CSF1 stimuli, ROS significantly decreased by about 40.1% on exposure to NMN supplement, ROS significantly decreased over one-fold on exposure to H2O2 stimuli, ROS significantly increased by more than one-fold. CSF1 co-supplement with NMN raised the ROS level in NMN-treated oocytes to close to the control level CSF1 co-supplement with H2O2 reduced the ROS level in H2O2- treated oocytes to near the control level. (E) Model hypothesis for (A–D) CSF1-induced IgG increment might be used to eliminate ROS production on exposure to either CSF1 or H2O2 treatment. (F, G) ROS live fluorescence shows that on exposure to CSF1 stimuli, ROS significantly decreased by about 53.7% while IgG co-inhibition significantly raised the ROS level close to the control level. On exposure to H2O2 stimuli, ROS significantly increased by more than one-fold the CSF1 co-supplement reduced the ROS level in H2O2-treated oocytes to close to the control, whereas IgG inhibition+CSF1+H2O2 significantly increased the ROS level compared with the CSF1+H2O2 group. (H) Model hypothesis for A-G: CSF1 treatment could induce both IgG and ROS increment increased IgG can be used to counteract the increment of ROS on exposure to CSF1 or H2O2 stimuli. (I-K) Western blot and quantification show that SOD2 significantly increased in response to CSF1, while decreased upon IgG inhibition or CSF1 treatment plus IgG inhibition GPX4 level was not affected by CSF1 treatment but decreased upon IgG inhibition. Actin was used as a loading control. Scale bars, 20 mm. Difference lower-case letters indicate significant difference between two groups.

Article Snippet: LPS (Cat#: L2880, Sigma, St. Louis, MO, USA) was added into oocyte IVMmedium at a final conc. of 10 EU/ml for 16 hour; CSF1 (Cat#: HZ-1207, Proteintech, Rosemont, IL, USA) was added into oocyte IVMmedium at a final conc. of 10 ng/ml for 16 hour; H2O2 (Cat#:88597,Sigma,St.Louis,MO,USA)wasadded intooocyte IVM medium at a final conc. of 30 mM for 30 min; NMN (Cat#: S5259, Selleck Chemicals, Houston, TX, USA) was added into oocyte IVM medium at a final conc. of 1mM for 16 hour; SC75741 (Cat#: S7273, Selleck Chemicals, Houston, TX, USA) was added into oocyte IVM medium at a final conc. of 0.1 mM for 16 hour.

Techniques: Western Blot, Control, Inhibition

Journal: International immunopharmacology

Article Title: NOX2 deficiency promotes GSDME-related pyroptosis by reducing AMPK activation in neutrophils.

doi: 10.1016/j.intimp.2024.113504

Figure Lengend Snippet: Fig. 1. NOX2 activation is regulated by autoimmune components. Neutrophils were treated with either IFN-α, IFN-γ, G-CSF, GM-CSF, TNF-α, complement C3 (C3) or PMA (positive control), and the representative curves and quantification of the rate of O2

Article Snippet: Stimulation concentrations were as follows unless indicated otherwise: 200 ng/ml phorbol 12-myristate 13-acetate (TargetMol, 16561- 29-8), 2000 IU/ml IFN-α (MCE, HY-P7023), 1000 ng/ml IFN-γ (MCE, HY-P7025), 20 ng/ml G-CSF (MCE, HY-P70422), 20 ng/ml GM-CSF (MCE, HY-P7016A), 200 pg/ml TNF-α (MCE, HY-P7058), 100 ng/ml Complement C3/C3a (MCE, HY-P7862).

Techniques: Activation Assay, Positive Control

Journal: International journal of molecular sciences

Article Title: A NOTCH1 Mutation Found in a Newly Established Ovarian Cancer Cell Line (FDOVL) Promotes Lymph Node Metastasis in Ovarian Cancer.

doi: 10.3390/ijms24065091

Figure Lengend Snippet: Figure 3. CSF3 is determined as the downstream effector of NOTCH1-p.C720fs mutation on epithelial- mesenchymal transition. (A,B) CXCL1, CXCL2, CXCL3, CXCL8, CSF3 and IL1B were determined

Article Snippet: Similarly, immunohistochemistry (IHC) was conducted to assess the expression of Ki67 (1:200, AF0198, Affinity, San Francisco, CA, USA), CyclinD1 (1:250, ab134175, Abcam), Hes1 (1:200, ab108937, Abcam), N-cadherin (1:200, #13116, Cell Signaling Technology, Danvers, MA, USA), vimentin (1:200, #5741, Cell Signaling Technology) and CSF3 (1:200, 17185-1-AP, Proteintech) in the tumors extracted from mice.

Techniques: Mutagenesis

Journal: International journal of molecular sciences

Article Title: A NOTCH1 Mutation Found in a Newly Established Ovarian Cancer Cell Line (FDOVL) Promotes Lymph Node Metastasis in Ovarian Cancer.

doi: 10.3390/ijms24065091

Figure Lengend Snippet: Figure 5. NOTCH1 mutations are more prominent in metastatic lymph nodes of ovarian cancer than in other implant metastatic sites. (A,B) Ten paired abdominal implant lesions and metastatic lymph nodes of ovarian cancer were subjected to WES and IHC detection to assess the difference of driver genes and the expression of downstream CSF3 in implant lesions and metastatic lymph nodes. (A) The heat map of driver genes in 10 paired abdominal implant lesions and metastatic lymph nodes of ovarian cancer. (B) The expression level of CSF3 in lymph nodes harboring mutated NOTCH1 was significantly higher than that with wild-type NOTCH1. The representative image of scoring criteria on the expression of CSF3: “no staining”, “weak staining”, and “strong staining”, with the quantitative analysis of H score shown on the right. * p < 0.05.

Article Snippet: Similarly, immunohistochemistry (IHC) was conducted to assess the expression of Ki67 (1:200, AF0198, Affinity, San Francisco, CA, USA), CyclinD1 (1:250, ab134175, Abcam), Hes1 (1:200, ab108937, Abcam), N-cadherin (1:200, #13116, Cell Signaling Technology, Danvers, MA, USA), vimentin (1:200, #5741, Cell Signaling Technology) and CSF3 (1:200, 17185-1-AP, Proteintech) in the tumors extracted from mice.

Techniques: Expressing, Staining

Journal: Pharmaceutical research

Article Title: Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product.

doi: 10.1007/s11095-018-2491-5

Figure Lengend Snippet: Fig. 1 Overlay of RP-HPLC chromatograms of endoproteinase Glu-C digested of Filgrastim CRS, Neupogen batch 1056681, Tevagrastim, copy products and several batches of Neupogen.

Article Snippet: Filgrastim CRS (EDQM) was used as a control.

Techniques:

Journal: Pharmaceutical research

Article Title: Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product.

doi: 10.1007/s11095-018-2491-5

Figure Lengend Snippet: Fig. 2 Circular dichroism spectra of filgrastim products at (a) 25 and (b) 55°C. Average curve represents the spectra of the expired bathes of Neupogen (black line), Neupogen batch 1056681 (red line), Tevagrastim (blue line), Biocilin (green line) and PDgrastim (pink line).

Article Snippet: Filgrastim CRS (EDQM) was used as a control.

Techniques: Circular Dichroism

Journal: Pharmaceutical research

Article Title: Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product.

doi: 10.1007/s11095-018-2491-5

Figure Lengend Snippet: Fig. 3 Thermal stability of selected filgrastim products monitored by (a) circular dichroism at 222 nm and (b) intrinsic fluorescence from 25 to 70°C. Average curves represent the results for expired batches of Neupogen (black line), Neupogen batch 1056681 (red line), Tevagrastim (blue line), Biocilin (green line) and PDgrastim (pink line).

Article Snippet: Filgrastim CRS (EDQM) was used as a control.

Techniques: Circular Dichroism, Fluorescence

Journal: Pharmaceutical research

Article Title: Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product.

doi: 10.1007/s11095-018-2491-5

Figure Lengend Snippet: Fig. 4 Filgrastim products on 4–12% Bolt® BisTris gel visualized by silver staining. Neupogen (NE) batch 1042036A, PDgrastim (PD), Zarzio (ZA), Tevagrastim (TE) and Biocilin (BI) as well as additional batches of Neupogen (A-G).

Article Snippet: Filgrastim CRS (EDQM) was used as a control.

Techniques: Silver Staining

Journal: Pharmaceutical research

Article Title: Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product.

doi: 10.1007/s11095-018-2491-5

Figure Lengend Snippet: Fig. 6 RP-UPLC chromatograms of (a) filgrastim CRS, (b) biosimilar and copy filgrastim products, and (c) expired batches of Neupogen compared to non-expired Neupogen.

Article Snippet: Filgrastim CRS (EDQM) was used as a control.

Techniques:

Journal: Pharmaceutical research

Article Title: Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product.

doi: 10.1007/s11095-018-2491-5

Figure Lengend Snippet: Fig. 7 Representative images of protein-like and silicone oil droplet- like particles observed by MFI in selected filgrastim products.

Article Snippet: Filgrastim CRS (EDQM) was used as a control.

Techniques: